Company registration number 08758564 (England and Wales)
ARC PHARMA (UK) LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
ARC PHARMA (UK) LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
ARC PHARMA (UK) LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
945,914
904,069
Investments
4
50,000
50,000
995,914
954,069
Current assets
Debtors
5
1,818,944
1,051,611
Investments
6
50,000
50,000
Cash at bank and in hand
608,386
312,938
2,477,330
1,414,549
Creditors: amounts falling due within one year
7
(1,364,160)
(913,320)
Net current assets
1,113,170
501,229
Total assets less current liabilities
2,109,084
1,455,298
Creditors: amounts falling due after more than one year
8
(257,046)
(343,067)
Provisions for liabilities
(235,923)
(225,768)
Net assets
1,616,115
886,463
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
1,616,015
886,363
Total equity
1,616,115
886,463
ARC PHARMA (UK) LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2024
31 December 2024
- 2 -

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 1 September 2025 and are signed on its behalf by:
Mr AJ Patel
Director
Company registration number 08758564 (England and Wales)
ARC PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

Arc Pharma (UK) Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 3 Curo Park, Frogmore, St. Albans, Hertfordshire, AL2 2DD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates. Turnover represents revenue generated from the laboratory testing services provided in the normal course of business.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

1.3
Tangible fixed assets

Tangible fixed asset under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Short leasehold
Over the lease term
Plant and machinery
25% on reducing balance
Fixtures and fittings
25% on reducing balance
Computer equipment
25% on reducing balance
Motor vehicles
25% on reducing balance
1.4
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

ARC PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

ARC PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
1.8
Retirement benefits

The company operates a defined contribution pension scheme. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Statement of income and retained earnings when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

1.9
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
45
40
3
Tangible fixed assets
Short leasehold
Plant and machinery
Fixtures and fittings
Computer equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 January 2024
5,670
1,174,950
105,824
287,440
489,604
2,063,488
Additions
-
0
303,853
13,076
40,049
-
0
356,978
At 31 December 2024
5,670
1,478,803
118,900
327,489
489,604
2,420,466
Depreciation and impairment
At 1 January 2024
2,883
785,826
78,030
169,832
122,848
1,159,419
Depreciation charged in the year
567
173,244
10,218
39,415
91,689
315,133
At 31 December 2024
3,450
959,070
88,248
209,247
214,537
1,474,552
ARC PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
3
Tangible fixed assets
Short leasehold
Plant and machinery
Fixtures and fittings
Computer equipment
Motor vehicles
Total
£
£
£
£
£
£
(Continued)
- 6 -
Carrying amount
At 31 December 2024
2,220
519,733
30,652
118,242
275,067
945,914
At 31 December 2023
2,787
389,124
27,794
117,608
366,756
904,069

Included within the net book value of the above asset is £287,972 (2023: £383,963) relating to assets held under hire purchase agreements. The depreciation charged to the financial statements in the year in respect of such assets amounted to £95,991 (2023: £127,988).

 

4
Fixed asset investments
2024
2023
£
£
Other investments other than loans
50,000
50,000

The above investments consist of a subscription of Class A common stock in Seecubic, Inc., a company registered in the USA.

5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
1,726,051
913,790
Other debtors
51,837
91,837
Prepayments and accrued income
41,056
45,984
1,818,944
1,051,611

Included within trade debtors above are factored debts of £1,726,051 which remain outstanding as at the balance sheet date.

6
Current asset investments
2024
2023
£
£
Loan notes
50,000
50,000

The above investments consist of the loan notes subscribed in Seecubic, Inc. with a maturity date of 31 December 2025. Seecubic, Inc. is a company registered in the USA.

ARC PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
7
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
10,375
150,789
Trade creditors
591,851
364,550
Taxation and social security
577,816
240,178
Other creditors
184,118
157,803
1,364,160
913,320
8
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
5,267
15,641
Other creditors
251,779
327,426
257,046
343,067
9
Loans and overdrafts
2024
2023
£
£
Bank loans
15,642
57,231
Bank overdrafts
-
0
109,199
15,642
166,430
Payable within one year
10,375
150,789
Payable after one year
5,267
15,641
10
Finance lease obligations
2024
2023
Future minimum lease payments due under finance leases:
£
£
Within one year
80,272
124,058
In two to five years
251,779
327,426
332,051
451,484

The above disclosed hire purchase contract has a fixed interest rate and is secured over the asset held under hire purchase lease commitments.

11
Operating lease commitments
ARC PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
11
Operating lease commitments
(Continued)
- 8 -

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
Total commitments
541,091
356,918
12
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Consultancy fees
2024
2023
£
£
Entities with common shareholders and directors
717,570
381,850
2024-12-312024-01-01falsefalsefalse01 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr S PatelMrs SK PipaliyaMr AJ Patel087585642024-01-012024-12-31087585642024-12-31087585642023-12-3108758564core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3108758564core:PlantMachinery2024-12-3108758564core:FurnitureFittings2024-12-3108758564core:ComputerEquipment2024-12-3108758564core:MotorVehicles2024-12-3108758564core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3108758564core:PlantMachinery2023-12-3108758564core:FurnitureFittings2023-12-3108758564core:ComputerEquipment2023-12-3108758564core:MotorVehicles2023-12-3108758564core:ShareCapital2024-12-3108758564core:ShareCapital2023-12-3108758564core:RetainedEarningsAccumulatedLosses2024-12-3108758564core:RetainedEarningsAccumulatedLosses2023-12-3108758564bus:Director32024-01-012024-12-3108758564core:LandBuildingscore:LongLeaseholdAssets2024-01-012024-12-3108758564core:PlantMachinery2024-01-012024-12-3108758564core:FurnitureFittings2024-01-012024-12-3108758564core:ComputerEquipment2024-01-012024-12-3108758564core:MotorVehicles2024-01-012024-12-31087585642023-01-012023-12-3108758564core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3108758564core:PlantMachinery2023-12-3108758564core:FurnitureFittings2023-12-3108758564core:ComputerEquipment2023-12-3108758564core:MotorVehicles2023-12-31087585642023-12-3108758564core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-01-012024-12-3108758564core:CurrentFinancialInstruments2024-12-3108758564core:CurrentFinancialInstruments2023-12-3108758564core:Non-currentFinancialInstruments2024-12-3108758564core:Non-currentFinancialInstruments2023-12-3108758564core:WithinOneYear2024-12-3108758564core:WithinOneYear2023-12-3108758564core:BetweenTwoFiveYears2024-12-3108758564core:BetweenTwoFiveYears2023-12-3108758564bus:PrivateLimitedCompanyLtd2024-01-012024-12-3108758564bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3108758564bus:FRS1022024-01-012024-12-3108758564bus:AuditExemptWithAccountantsReport2024-01-012024-12-3108758564bus:Director12024-01-012024-12-3108758564bus:Director22024-01-012024-12-3108758564bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP